INTRODUCTION {#s1}
============

The International Agency for Research on Cancer has confirmed that ionizing radiation is associated with an increased risk for a wide range of cancers, including breast cancer, thyroid cancer, and leukemia \[[@R1]\]. The risk for carcinogenesis associated with radiation exposure is influenced by genetic background \[[@R2], [@R3]\]. Understanding gene--environment interactions in carcinogenesis has been a stated priority for the National Cancer Institute \[[@R4]\].

The ataxia telangiectasia-mutated (*ATM*) protein plays a central role in mediating the cellular response to radiation-induced DNA damage \[[@R5]\]. Germ-line inactivating mutations in the *ATM* gene cause ataxia-telangiectasia, a recessive genetic disorder with a high incidence of cancer \[[@R6]\]. Ataxia-telangiectasia heterozygotes appear to have a greater risk of developing cancer than the wild-type homozygotes, leading to the estimation that polymorphisms in the *ATM* gene may alter the risk of carcinogenesis \[[@R7]\]. In the past two decades, about 100 studies have been published to evaluate the associations of *ATM* genetic polymorphisms with cancer risk. Some of the polymorphisms have been reported by more than 10 studies, such as rs1801516, IVS10-6T \> G, rs1800057, rs1800054, rs1800056, rs1800058, and rs4986761. Although most of the findings on these polymorphisms were inconsistent, a meta-analysis of 11120 participants showed a significant association between the rs1800057 polymorphism and breast cancer risk \[[@R8]\]. Recently, two meta-analyses demonstrated evidence for gene-environment interactions between the *ATM* gene and radiation exposure in the development of radiotherapy-induced adverse events \[[@R9], [@R10]\]. Taken together, these suggest a possible role of *ATM* genetic polymorphisms in carcinogenesis through gene--radiation interactions.

A number of studies have investigated the joint effect between the *ATM* gene and radiation exposure on cancer risk. The first study published in 2002 showed that polymorphisms in the *ATM* gene were not associated with an increased breast cancer risk in patients with Hodgkin\'s disease after radiotherapy \[[@R11]\]. Subsequently, 5 studies have been conducted on this issue, with inconsistent results \[[@R12]--[@R16]\]. Given the uncertainty and the lack of a meta-analysis on this topic, we conducted two meta-analyses of *ATM* genetic polymorphisms and cancer risk in individuals in the presence or absence of radiation exposure to determine whether there was a joint effect between the *ATM* gene and radiation exposure in carcinogenesis.

RESULTS {#s2}
=======

Assessing quality of included studies {#s2_1}
-------------------------------------

rs1801516 was the only *ATM* genetic polymorphism investigated by more than 3 studies of radiation exposure, and was eligible for the present study. A total of 29 studies were identified for the meta-analysis of individuals without radiation exposure \[[@R12], [@R17]--[@R44]\], and 6 studies for the meta-analysis of individuals with radiation exposure \[[@R11]--[@R16]\] (Figure [1](#F1){ref-type="fig"}). The *ATM* rs1801516 genotype distribution in controls was not in Hardy--Weinberg equilibrium (HWE) in 5 studies \[[@R12], [@R18]--[@R21]\], could not be assessed in 4 studies \[[@R11], [@R13], [@R25], [@R26]\], and was in HWE for the other studies \[[@R17], [@R22]--[@R24], [@R27]--[@R44]\]. As a result, 5 studies were identified with methodological errors and were excluded from a meta-analysis \[[@R12], [@R18]--[@R21]\]. The quality assessments according to Newcastle--Ottawa scale (NOS) \[[@R45]\] were described in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. The included studies had a relatively high quality with a median score of 7, ranging from 5 to 9. The quality was high for 22 studies (≥ 6) \[[@R11]--[@R16], [@R25], [@R26], 28--[@R30], [@R32]--[@R40], [@R42], [@R43]\] and low for 8 studies (≤ 5) \[[@R17], [@R22]--[@R24], [@R27], [@R31], [@R41], [@R44]\].

![Flow chart for inclusion and exclusion of studies\
^a^The search on Chinese National Knowledge Infrastructure (CNKI) database identified no study of the *ATM* rs1801516 polymorphism and cancer risk. ^b^5 studies were identified with methodological errors and were excluded from the present meta-analysis in the subsequent quality assessment procedure \[[@R12], [@R18]--[@R21]\]. ^c^One article reported data for radiation exposed as well as unexposed populations, the results for each group were considered as a separate study \[[@R12]\]](oncotarget-07-76867-g001){#F1}

Meta-analysis for individuals in the absence of radiation exposure {#s2_2}
------------------------------------------------------------------

This meta-analysis included 24 studies with 9858 cases and 13475 controls \[[@R17], [@R22]--[@R44]\] (Table [1](#T1){ref-type="table"}). When all cancer types were considered, there was no significant association of the rs1801516 polymorphism with cancer risk (homozygous model: odds ratio \[OR\] = 0.84, 95% confidence interval \[CI\]: 0.68, 1.03, *P* = 0.074; heterozygous model: OR = 0.99, 95%CI: 0.91, 1.07, *P* = 0.784; recessive model: OR = 0.87, 95%CI: 0.69, 1.10, *P* = 0.231; dominant model: OR = 0.97, 95%CI: 0.89, 1.06, *P* = 0.632). There was little evidence of heterogeneity across studies (I^2^ ≤ 29.1%). Subgroup analyses were conducted in order to check whether the features of the included studies affected the results of this meta-analysis. For each genetic model, there was little variation in the effect sizes according to cancer site, ethnicity, study quality, and study size. Figures [2](#F2){ref-type="fig"}--[3](#F3){ref-type="fig"} showed the forest plot of the association under the homozygous and dominant models, and Tables [2](#T2){ref-type="table"}--[3](#T3){ref-type="table"} showed the subgroup analyses under the homozygous and dominant models. The results under the heterozygous and recessive models were similar to those under the dominant and homozygous models, and thus were not shown in figures and tables. For all the meta-analyses, sensitivity analyses did not identify any single study that markedly influenced the estimates, indicating that these results were reliable.

###### Characteristics of studies included in the meta-analysis of individuals in the absence of radiation exposure

  First author, year \[Ref.\]               Ethnicity                                          Region/Country   Type of cancer                        Family history of cancer   HWE in controls   Minor allele frequency   Cases/controls
  ----------------------------------------- -------------------------------------------------- ---------------- ------------------------------------- -------------------------- ----------------- ------------------------ ----------------
  Maillet P, 2000, \[[@R44]\]               Swiss                                              Switzerland      Colorectal cancer                     Yes                        Yes               0.14                     46/163
  Buchholz TA, 2004, \[[@R43]\]             Mixed population (75% Caucasian)                   USA              Breast cancer                         No                         Yes               0.14                     58/528
  Heikkinen K, 2005, \[[@R42]\]             Finnish                                            Finland          Breast cancer                         Yes                        Yes               0.25                     121/306
  Gonzalez-Hormazabal P, 2008, \[[@R41]\]   Chilean                                            Chile            Breast cancer                         Yes                        Yes               0.07                     126/200
  Angele S, 2003, \[[@R40]\]                NR                                                 France           Breast cancer                         No                         Yes               0.13                     254/312
  Renwick A, 2006, \[[@R39]\]               UK ethnic(whites)                                  UK               Breast cancer                         Yes                        Yes               0.16                     443/521
  Angele S, 2004, \[[@R38]\]                Caucasian                                          UK               Prostate cancer                       No                         Yes               0.17                     628/445
  Yang H, 2007, \[[@R37]\]                  Caucasian                                          USA              Non-small cell lung cancer            No                         Yes               \> 0.05                  544/546
  Tommiska J, 2006, \[[@R36]\]              Finnish                                            Finland          Breast cancer                         Both                       Yes               0.24                     1581/702
  Wu X, 2006, \[[@R35]\]                    Whites (89.3%)                                     USA              Bladder cancer                        No                         Yes               0.14                     608/592
  Sommer SS, 2002, \[[@R34]\]               Caucasian (\> 80%)                                 USA              Breast cancer                         No                         Yes               0.13                     43/43
  Xu L, 2012, \[[@R33]\]                    Non-hispanic whites; mixed population              USA              Thyroid carcinoma                     No                         Yes               \> 0.10                  592/885
  Margulis V, 2008, \[[@R32]\]              NR                                                 USA              Renal cancer                          No                         Yes               0.14                     323/337
  Al-Hadyan KS, 2012, \[[@R31]\]            NR                                                 Saudi Arabia     Head and neck cancer                  No                         Yes               0.07                     156/251
  Schrauder M, 2008, \[[@R30]\]             NR                                                 German           Breast cancer                         No                         Yes               0.15                     514/511
  Dork T, 2001, \[[@R29]\]                  Caucasian                                          Germany          Breast cancer                         No                         Yes               0.13                     1000/325
  Wojcicka A, 2014, \[[@R28]\]              Caucasian                                          Poland           Thyroid cancer                        No                         Yes               0.11                     1603/1844
  Kristensen AT, 2004, \[[@R27]\]           NR                                                 Norway           Rectal cancer                         No                         Yes               0.17                     151/3526
  Hirsch AE, 2008, \[[@R26]\]               African-American                                   USA              Breast cancer                         No                         NR                \> 0.05                  37/95
  Bretsky P, 2003, \[[@R25]\]               African-American, Latina,Japanese, and Caucasian   USA              Breast cancer                         No                         NR                \> 0.03                  428/426
  Pereda CM, 2015, \[[@R24]\]               mixed                                              Cuban            Thyroid cancer                        No                         Yes               0.11                     197/206
  Tecza K, 2015, \[[@R23]\]                 Caucasian                                          Poland           Ovarian cancer                        No                         Yes               0.13                     223/335
  Meier M, 2005, \[[@R22]\]                 Caucasian                                          Germany          T cell acute lymphoblastic leukemia   No                         Yes               0.13                     103/96
  Oliveira S, 2012, \[[@R17]\]              Portuguese                                         Portugal         Cervical cancer                       No                         Yes               0.17                     79/280

Abbreviations: HWE, Hardy--Weinberg equilibrium.

###### Subgroup analyses for the association between the ATM rs1801516 polymorphism and cancer risk in individuals in the absence of radiation exposure under the homozygous model

  Study selection                                               Studies (*n*)   Cases      Controls   Heterogeneity   Effect                       
  ------------------------------------------------------------- --------------- ---------- ---------- --------------- -------- ------------------- -------
  Quality score                                                                                                                                    
   ≥ 6                                                          12              174/5195   187/4683   0.0             0.858    0.81 (0.65--1.01)   0.060
   ≤ 5                                                          8               11/804     122/3608   0.0             0.617    0.99 (0.53--1.83)   0.976
  Sample size                                                                                                                                      
   Large (\> 500)                                               12              173/5341   274/7144   0.0             0.675    0.82 (0.66--1.02)   0.081
   Small (\< 500)                                               8               12/658     35/1147    0.0             0.909    0.98 (0.52--1.86)   0.962
  Family history of cases[^b^](#tfn_002){ref-type="table-fn"}                                                                                      
   Sporadic cancer                                              16              137/4989   264/7452   0.0             0.960    0.88 (0.70--1.11)   0.269
   Family cancer                                                5               48/1010    83/1243    4.1             0.947    0.71 (0.49--1.03)   0.071
  Ethnicity                                                                                                                                        
   Caucasion                                                    17              183/5615   307/7737   0.0             0.941    0.82 (0.67--1.02)   0.066
  Site                                                                                                                                             
   Breast                                                       9               110/2889   119/2404   0.0             0.704    0.76 (0.57--1.01)   0.060
  Sum                                                           20              185/5999   309/8291   0.0             0.887    0.84 (0.68--1.03)   0.074

AA represents the number of individuals who carry the AA alleles. GG represents the number of individuals who carry the GG alleles. Abbreviations: CI, confidence interval; HWE, Hardy--Weinberg equilibrium; OR, odds ratio.

The genotype distribution in controls was in HWE in all the studies.

The study by Tommiska et al. \[[@R36]\] reported the risks of both familial and sporadic cancer in comparison with the same controls, and the results for each were considered as a separate study.

###### Subgroup analyses for the association between the *ATM* rs1801516 polymorphism and cancer risk in individuals in the absence of radiation exposure under the dominant model

  Study selection                                               Studies (*n*)   Cases       Controls    Heterogeneity   Effect                       
  ------------------------------------------------------------- --------------- ----------- ----------- --------------- -------- ------------------- -------
  Quality score                                                                                                                                      
   ≥ 6                                                          15              2145/6088   2035/5837   32.4            0.103    0.92 (0.85--1.00)   0.054
   ≤ 5                                                          8               277/804     1452/3608   0.0             0.705    1.18 (1.00--1.41)   0.058
  Sample size                                                                                                                                        
   Large (\> 500)                                               14              2201/6205   3069/8220   0.052           41.5     0.95 (0.86--1.05)   0.325
   Small (\< 500)                                               9               221/687     418/1225    0.573           0.0      1.06 (0.87--1.30)   0.536
  Family history of cases[^a^](#tfn_003){ref-type="table-fn"}                                                                                        
   Familial cancer                                              5               504/1010    649/1243    0.169           37.8     0.91 (0.79--1.06)   0.214
   Sporadic cancer                                              19              1902/5665   3115/8428   0.170           23.6     0.97 (0.90--1.04)   0.352
  Ethnicity                                                                                                                                          
   Caucasian                                                    19              2279/6068   3320/8345   0.126           27.9     0.95 (0.88--1.02)   0.114
  Site                                                                                                                                               
   Breast                                                       11              1306/3299   1107/2862   0.085           39.5     0.95 (0.81--1.10)   0.462
   Thyroid                                                      3               495/1897    621/2314    0.304           16.1     0.96 (0.84--1.10)   0.571
  HWE in controls                                                                                                                                    
   Yes                                                          21              2367/6482   3423/8988   0.073           32.9     0.96 (0.89--1.03)   0.640
  Overall                                                       23              2422/6892   3487/9445   0.114           27.1     0.97 (0.89--1.06)   0.632

AA + AG represents the number of individuals who carry the AA or AG alleles. GG represents the number of individuals who carry the GG alleles. Abbreviations: CI, confidence interval; HWE, Hardy--Weinberg equilibrium; OR, odds ratio.

The study by Tommiska et al. \[[@R36]\] reported the risks of both familial and sporadic cancer in comparison with the same controls, and the results for each were considered as a separate study.

![Association between the *ATM* rs1801516 polymorphism and cancer risk in individuals in the absence of radiation exposure under the homozygous model\
AA represents the number of individuals who carry the AA alleles. GG represents the number of individuals who carry the GG alleles. ORs for each study are represented by the squares, and the horizontal line crossing the square represents the 95% CI. The diamond represents the estimated overall effect based on the meta-analysis. ORs and 95%CIs were computed by applying a continuity correction (addition of 0.5 in all the cells) in order to overcome problems resulted from cells containing zero values \[[@R69]\]. All statistical tests were two sided. Abbreviations: CI, confidence interval; OR, odds ratio](oncotarget-07-76867-g002){#F2}

![Association between the *ATM* rs1801516 polymorphism and cancer risk in individuals in the absence of radiation exposure under the dominant model\
AA + AG represents the number of individuals who carry the AA or AG alleles. GG represents the number of individuals who carry the GG alleles. ORs for each study are represented by the squares, and the horizontal line crossing the square represents the 95% CI. The diamond represents the estimated overall effect based on the meta-analysis. All statistical tests were two sided. Abbreviations: CI, confidence interval; OR, odds ratio](oncotarget-07-76867-g003){#F3}

We examined if there was evidence of publication bias for each meta-analysis that included 10 or more studies. Asymmetry in the funnel plots was not observed under any comparisons, and significant asymmetry was not suggested by Egger\'s linear regression test or Begg\'s rank correlation test ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}).

Meta-analysis for individuals in the presence of radiation exposure {#s2_3}
-------------------------------------------------------------------

There were 6 studies with 1459 cases and 2328 controls eligible for this meta-analysis \[[@R11]--[@R16]\]. The main characteristics of these studies were presented in Table [4](#T4){ref-type="table"}. 2 out of 6 studies investigated the association between the rs1801516 polymorphism and contralateral breast cancer risk in breast cancer patients after radiotherapy \[[@R13], [@R14]\], 1 study investigated the association between the rs1801516 polymorphism and breast cancer risk in patients with Hodgkin\'s disease after radiotherapy \[[@R11]\], and 3 studies investigated the association between the rs1801516 polymorphism and papillary thyroid carcinoma risk in individuals who lived in the areas contaminated by radionuclides \[[@R12], [@R15], [@R16]\]. 5 out of 6 studies were conducted in Caucasians \[[@R11]--[@R15]\], and 1 in Polynesians \[[@R16]\]. All the included studies had used histologic analyses to confirm cancers.

###### Characteristics of studies included in the meta-analysis of individuals in the presence of radiation exposure

  **First author, year \[Ref.\]**                                      **Ethnicity**   **Region/Country**        **Investigation arm**                                                                                                                                                                                                                                                                                                                                                                                                        **Control arm**                                                                                                                                                                                                                           **Family history of cases**   **HWE in controls**   **Minor allele frequency**   **Cases/controls**
  -------------------------------------------------------------------- --------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- --------------------- ---------------------------- --------------------
  Akulevich NM, 2009, \[[@R12]\][^a^](#tfn_003){ref-type="table-fn"}   Caucasian       European part of Russia   IR-induced thyroid cancer (Cases lived in the areas contaminated with radionuclides from Chernobyl fallouts; the cases were younger than 15 years at the time of the Chernobyl accident; The median time to develop PTC was 14 years.)                                                                                                                                                                                       IR-exposed controls (the controls were matched to the cases by age and geographic region.)                                                                                                                                                No                            Yes                   0.17                         122/198
  Damiola F, 2014, \[[@R15]\][^a^](#tfn_004){ref-type="table-fn"}      Caucasian       Belarus                   IR-induced thyroid cancer (cases lived in the areas contaminated with radionuclides from Chernobyl fallouts. At the time of the Chernobyl accident, the cases were younger than 18 years old; the cases were diagnosed within 6--12 years after the accident.)                                                                                                                                                               IR-exposed controls (residents of the same settlements as the cases. Age of IR-exposed controls was set to be ± 3 years of the cases.)                                                                                                    No                            Yes                   0.16                         70/250
  Broeks A, 2008, \[[@R13]\]                                           Caucasian       Netherlands               Therapy-induced contralateral breast cancer (the first breast cancer was diagnosed before age 50. There is an interval of at least 1 year between the first and the second breast cancer.)                                                                                                                                                                                                                                   Unilateral breast cancer (the first breast cancer was diagnosed before age 50. The patients were disease-free of a second breast cancer for at least 5 years.)                                                                            No                            NR                    \> 0.10                      247/190
  Concannon P, 2008, \[[@R14]\]                                        Caucasian       USA                       Therapy-induced contralateral breast cancer (the first breast cancer was diagnosed before age 55. There is an interval of at least 1 year between the first and the second breast cancer. Median interval between first diagnosis and reference date was 4.3 years.)                                                                                                                                                         Unilateral breast cancer (the first breast cancer was diagnosed before age 55. The patients were disease-free of a second breast cancer for at least 1 year. Median interval between first diagnosis and reference date was 4.3 years.)   No                            Yes                   0.13                         808/1397
  Offit K, 2002, \[[@R11]\]                                            Caucasian       USA                       Radiation-induced breast cancer after treatment for Hodgkin\'s disease (The median time to develop breast cancer was 18 years.)                                                                                                                                                                                                                                                                                              Patients with Hodgkin\'s disease who did not develop breast cancer (The median follow-up was 17 years.)                                                                                                                                   No                            NR                    NR                           37/23
  Maillard S, 2015, \[[@R16]\]                                         Polynesian      France                    IR-induced thyroid cancer (Cases lived in the areas where a total of 41 atmospheric nuclear weapons tests were carried out between 1966 and 1974 and where individuals were at an increased risk of developing thyroid cancer caused by radionuclides \[[@R74]\]. All cases were under the age of 15 in 1974, and all were diagnosed for thyroid cancer between 1979 and 2004. Age distribution was ranged from 10 to 62.)   IR-exposed controls (the controls were matched to the cases by race, age and geographic region.)                                                                                                                                          No                            Yes                   0.02                         175/270

Abbreviations: HWE, Hardy--Weinberg equilibrium; IR, ionizing radiation.

There is no overlap in the participants between the two studies \[[@R12], [@R15]\].

To include all 6 studies for a summary OR estimate, the meta-analysis could only be conducted under the dominant model. The result showed a significant association between the rs1801516 polymorphism and a decreased risk of radiation-induced cancer (OR = 0.64, 95% CI: 0.41, 0.99; *P* = 0.044), with high between study heterogeneity (I^2^ = 71.4%, *P* = 0.004) (Figure [4](#F4){ref-type="fig"}). Sensitivity analyses identified that the study by Maillard et al. was the outlier, and the association was more significant after this study was excluded (OR = 0.55, 95% CI: 0.36, 0.83; *P* = 0.005) \[[@R16]\]. However, the heterogeneity remained significant (I^2^ = 66.9%, *P* = 0.017), indicating that other factors might contribute to the heterogeneity. Table [5](#T5){ref-type="table"} showed the results of the subgroup analyses. A significant association was shown among Caucasians (OR = 0.55, 95% CI: 0.36, 0.83; *P* = 0.005), whereas no association was shown among other subgroups. In addition, there was obvious evidence of heterogeneity in all subgroups (I^2^ ranged 66.9% to 81.8%), suggesting that the examined factors had a minimal influence on the variation of the estimates.

![Association between the *ATM* rs1801516 polymorphism and cancer risk in individuals in the presence of radiation exposure under the dominant model\
AA + AG represents the number of individuals who carry the AA or AG alleles. GG represents the number of individuals who carry the GG alleles. ORs for each study are represented by the squares, and the horizontal line crossing the square represents the 95% CI. The diamond represents the estimated overall effect based on the meta-analysis. All statistical tests were two sided. Abbreviations: CI, confidence interval; OR, odds ratio](oncotarget-07-76867-g004){#F4}

###### Subgroup analyses for the association between the *ATM* rs1801516 polymorphism and cancer risk in individuals in the presence of radiation exposure under the dominant model

  Study selection   Studies (*n*)   Cases      Controls   Heterogeneity   Effect                       
  ----------------- --------------- ---------- ---------- --------------- -------- ------------------- -------
  Sample size                                                                                          
   Small (\< 500)   4               86/565     198/733    68.1            0.014    0.58 (0.33--1.03)   0.065
  HWE in controls                                                                                      
   Yes              4               218/857    480/1635   75.2            0.007    0.75 (0.43--1.30)   0.300
  Ethnicity                                                                                            
   Caucasion        5               248/1036   529/1529   66.9            0.017    0.55 (0.36--0.83)   0.005
  Site                                                                                                 
   Breast           3               214/878    396/1214   67.5            0.046    0.61 (0.37--1.03)   0.063
   Thyroid          3               45/322     141/577    81.8            0.004    0.71 (0.26--1.97)   0.511
  Sum               6               259/1200   537/1791   71.4            0.004    0.64 (0.41--0.99)   0.044

AA + AG represents the number of individuals who carry the AA or AG alleles. GG represents the number of individuals who carry the GG alleles.

Abbreviations: CI, confidence interval; HWE, Hardy--Weinberg equilibrium; OR, odds ratio.

All the studies included in these analyses were scored as high quality, and all the participants included were classified as sporadic groups.

Differences in the effect estimates between individuals in the presence or absence of radiation exposure {#s2_4}
--------------------------------------------------------------------------------------------------------

The effect estimates for individuals in the absence and presence of radiation exposure were compared to determine the relationship of the interaction (synergistic or antagonistic) between radiation exposure and the rs1801516 polymorphism in carcinogenesis. Figure [5](#F5){ref-type="fig"} displayed the comparisons of the ORs between the main meta-analyses and between the subgroup analyses under the dominant model. The genetic effect for all participants in the presence of radiation exposure was borderline significantly larger than that for all participants in the absence of radiation exposure (radio of OR = 0.66, 95% CI: 0.42, 1.03; *P* = 0.066). The difference was statistically significant when only Caucasians were included (radio of OR = 0.58, 95% CI: 0.38, 0.88; *P* = 0.011).

![Odds ratios from the meta-analyses of individuals in the presence of radiation exposure were compared with odds ratios from the meta-analyses of individuals in the absence of radiation exposure (dominant model)\
ORs for each group are represented by the squares, and the horizontal line crossing the square represents the 95% CI. All statistical tests were two sided. Abbreviations: CI, confidence interval; OR, odds ratio. ^a^All the participants included in the meta-analysis of individuals in the presence of radiation exposure were classified as sporadic groups. ^b^All the studies included in the meta-analysis of individuals in the presence of radiation exposure were scored as high quality](oncotarget-07-76867-g005){#F5}

DISCUSSION {#s3}
==========

This work represents the first comprehensive assessment of the literature on the gene-environment interaction for polymorphisms in the *ATM* gene and radiation exposure in carcinogenesis. rs1801516, which was the only *ATM* genetic polymorphism investigated by more than 3 studies, was eligible for the present study. Our meta-analyses showed that the rs1801516 polymorphism interacted with radiation exposure, resulting in a synergistic effect in carcinogenesis. In addition, we showed convincing evidence of no association between the rs1801516 polymorphism and cancer risk for individuals in the absence of radiation exposure.

The present meta-analysis of 23333 participants in the absence of radiation exposure had a very large sample size, and was able to provide convincing evidence of no association between the rs1801516 polymorphism and cancer risk. Up to now, 5 meta-analyses have been performed for the role of the rs1801516 polymorphism on cancer risk: 4 on breast cancer \[[@R8], [@R46]--[@R48]\] and 1 on thyroid cancer \[[@R49]\]. One of the meta-analyses showed that homozygous carriers of the rs1801516 genotype had a lower breast cancer risk compared with carriers of the heterozygous and homozygous wild-type genotypes \[[@R48]\]. However, the other studies did not find a significant association between the rs1801516 polymorphism and cancer risk \[[@R8], [@R46], [@R47], [@R49]\]. Compared with the previous meta-analyses \[[@R8], [@R46]--[@R49]\], the present meta-analysis included more studies, and was able to employ rigorous methodology to estimate the genetic effect of the rs1801516 polymorphism on carcinogenesis. The overall meta-analyses of individuals in the absence of radiation exposure showed no association between the rs1801516 polymorphism and cancer risk under the four genetic models. We also conducted subgroup analyses based on cancer site, ethnicity, familial cancer history, study quality, and sample size. For each genetic model, we observed a small variability in the effect sizes between the subgroup analyses and the main meta-analysis. These suggested that the results of the main meta-analysis were independent on the features of the included studies. The extensive consistency provided optimal evidence of the credibility of no association between the rs1801516 polymorphism and cancer risk for individuals in the absence of radiation exposure.

Our meta-analysis of 3787 participants in the presence of radiation exposure provided evidence of an association between the rs1801516 polymorphism and a decreased cancer risk for individuals who exposed to radiation. This meta-analysis included 6 studies across two ethnicities: 1 study in Polynesians and 5 studies in Caucasions. The natures of the two populations are different: the Polynesians are geographically isolated from the rest of the world, and have a significant variation in allele frequencies (minor allele frequency \[MAF\] in Polynesians = 0.02) as compared to the Caucasians (MAF in Caucasians = 0.19) \[[@R16]\]. The study in Polynesians showed that the minor allele carriers of the rs1801516 polymorphism were associated with an increased cancer risk compared with the main allele carriers in the presence of radiation exposure \[[@R16]\]. On the contrary, all the other studies (Caucasians) showed a consistently decreased cancer risk of the minor allele carriers compared with the main allele carriers in the presence of radiation exposure (2 of 5 comparisons were individually significant \[[@R13], [@R15]\]). In addition, the test of interaction showed a significant difference in the effect estimates between Caucasions in the presence and absence of radiation exposure. Furthermore, two meta-analyses demonstrated convincing evidence of an association between the rs1801516 polymorphism and radiotherapy-induced adverse events \[[@R9], [@R10]\]. Taken together, these suggested a gene-environment interaction between the rs1801516 polymorphism and radiation exposure in carcinogenesis, and the interaction might be modified by ethnicity. However, we could not rule out the possibility that the observed association between the rs1801516 polymorphism and cancer risk of Polynesians in the presence of radiation exposure was a chance finding. It should be noted that there was a high variability across studies included in this meta-analysis. Our subgroup analyses failed to explain the heterogeneity, indicating that the study-level factors examined had little influence on the variation of the estimates.

The *ATM* rs1801516 polymorphism is a polymorphic G-to-A transition at nucleotide 5557 of exon 39, resulting in a change from aspartic acid to asparagine at amino acid position 1853 of the protein \[[@R50]\]. *In vitro* data showed that human fibroblasts carrying the minor alleles of the rs1801516 polymorphism increased cellular radiosensitivity compared with those carrying the major alleles \[[@R51], [@R52]\]. Some variants of the *ATM* gene, including the rs1801516 polymorphism, were reported to be associated with a decreased *ATM* expression and a reduced capacity of DNA damage recognition \[[@R42], [@R53]\]. Based on these data, it was difficult to figure out how this single polymorphism might be associated with a decreased cancer risk for individuals who were exposed to radiation. Instead, a gene-gene interaction of the *ATM* gene with BRCA1 has been reported \[[@R28], [@R52]\]. Therefore, it could be expected that the polygenic action of unidentified alleles or genes probably played a non-negligible role on the function of the rs1801516 polymorphism. The differences observed between Polynesians and Caucasians regarding the effect of the rs1801516 polymorphism on cancer risk following radiation exposure as well as the clinical heterogeneity were likely to be due to gene-gene interactions.

Our study has a number of possible limitations. 1) Due to fewer than 10 studies in the meta-analysis of individuals with radiation exposure, the publication bias was not tested by the funnel plot, for this method could not obtain enough power in the case \[[@R54]\]. However, based on the Venice criteria that assess cumulative evidence on genetic associations, an OR of \> 0.85 or \< 1.15 could be easily susceptible to biases, including phenotyping errors, genotyping errors, population stratification, and selective reporting biases \[[@R55]--[@R57]\]. This meta-analysis yielded an OR of 0.55, suggesting that this genetic effect was not so vulnerable to biases. 2) Except for the dominant model, other genetic models, such as recessive, heterozygous, and homozygous models, were not examined because of the limited information in the meta-analysis of individuals in the presence of radiation exposure. Therefore, the gene-environment interaction in other genetic models could not be determined. 3) Due to the lack of individual patient data, we were not able to conduct the present meta-analyses based on individual patient data, in which we can: (a) check each study to apply consistent conditions for inclusion and to standardize analysis techniques, and (b) adjust the analyses for covariates (radiation dose, gender, and age). It is especially so for the study by Broeks et al. that reported the significance of *ATM* variants on secondary breast cancer risk after treatment of primary breast cancer \[[@R13]\]. In this study, 32% patients included in the present meta-analysis did not receive radiotherapy \[[@R13]\]. Because the sensitivity analyses showed no difference in the effect estimates after exclusion of this study, we believed that the incomplete data might reduce the power of the analysis but did not bias it. Moreover, literature based meta-anlayses were considered to be often consistent with those based on individual patient data \[[@R58]\], and should not be viewed as "inferior" \[[@R59]\].

In conclusion, the present study gave a clear picture of gene-environment interaction for the *ATM* rs1801516 genotype and radiation exposure in carcinogenesis: there was convincing evidence of no association between the rs1801516 polymorphism and cancer risk of individuals in the absence of radiation exposure; there was evidence of a gene-environment interaction between the rs1801516 polymorphism and radiation exposure in carcinogenesis, and the heterogeneity observed across studies might be due to gender-ethnicity or gene-gene interactions. Further studies are needed to elucidate sources of the heterogeneity.

MATERIALS AND METHODS {#s4}
=====================

Our meta-analyses were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines \[[@R60]\].

Selection criteria {#s4_1}
------------------

To be eligible for inclusion in our meta-analyses, a study had to meet all the following criteria: (1) it should be a case-control, cross-sectional, or cohort study in humans; (2) it can be published in any language, but it must be a full-text paper in an international peer-reviewed journal before December 31, 2015; (3) there was no restriction on cancer type, but it must report adequate information on genotype frequencies to estimate ORs for the cancer type. Case reports, editorials, meta-analyses, and review articles were excluded.

A systematic literature search was conducted in Electronic databases, including PubMed, Web of Science, EMBASE, and Chinese National Knowledge Infrastructure (including China Doctoral/Master Dissertation Full-text Database, China Academic Journals Full-text Database, Century Journals Project, and China Proceedings of Conference Full-text Database), before December 31, 2015. We used the keywords: "(atm OR ataxia telangiectasia mutated) AND (polymorphism\* OR variant\* OR mutant\* OR genotype\*)", in the searching process. This search yielded 3816 articles.

To achieve adequate statistical power for the meta-analysis on gene-environment interactions in carcinogenesis, eligible polymorphisms were those reported by more than three data sources of radiation exposure. For this purpose, we employed a two-stage screen strategy (Figure [1](#F1){ref-type="fig"}). First, we collected articles on the association between *ATM* genetic polymorphisms and cancer risk in individuals in the presence of radiation exposure. After screened by title, abstract, or full text if necessary, we identified 6 articles including 17 polymorphisms. References from the relevant articles or reviews were also searched for additional studies. This search yielded no extra articles. Finally, we found that rs1801516 was the only *ATM* polymorphism investigated by more than 3 articles. Second, we collected articles on the association between the rs1801516 polymorphism and cancer risk in individuals in the absence of radiation exposure. We included all surrogates of the rs1801516 polymorphism, including rs52821794, rs60879649, rs17503060 (<http://www.ncbi.nlm.nih.gov/snp/>), and rs4988023 \[[@R61]\]. Our search on Chinese National Knowledge Infrastructure database identified no article on the rs1801516 polymorphism and cancer risk (possibly due to a low MAF of \< 0.05 in Asians \[[@R25], [@R62]\]. If different articles reported on the same sample, only the most complete information was included. If an article included multiple sources or study populations, data were extracted separately if possible. The article by Akulevich et al. studied radiation exposed populations as well as unexposed populations, the results for each group were considered as a separate study \[[@R12]\]. Finally, 29 studies without radiation exposure were identified to meet the inclusion criteria for subsequent quality assessment (Figure [1](#F1){ref-type="fig"}).

Data collection {#s4_2}
---------------

Two authors independently extracted data based on a standardized form. The following information was collected from each study: first author, year of publication, country of origin, ethnicity, family history of cases (familial cancer or sporadic cancer), MAF in controls, controls in HWE, cancer site, and number of genotyped cases and controls. Ethnicity was classified as African-American, Amerindian, Asian, Caucasian, or others based on the ethnicity of at least 80% of the study population \[[@R63]\]. When a study did not state the included ethnic groups, we considered the ethnicity of the source population based on the country where the study was performed \[[@R63]\]. When an article reported data for different ethnic groups, the results for each group were considered as a separate study. If it was impossible to separate participants according to ethnicity, the participants were considered as "others". Study authors were contacted when there was insufficient information. Disagreement was resolved by discussion between authors.

Quality assessment {#s4_3}
------------------

Two authors independently evaluated the quality of each study, with discrepancies resolved during a consensus meeting. We performed two types of quality assessments. The first one was the assessment of methodological errors. Deviation from HWE in controls is an indication of a genotyping error or selection bias \[[@R64], [@R65]\], and was considered as a methodological error. Because including studies with methodological errors may lower the quality of evidence in a meta-analysis \[[@R66]\], these studies were excluded. However, it should be noted: (1) in case-only studies, HWE deviations may reflect an association with the disease, rather than poor genotyping \[[@R67]\]; (2) studies with insufficient information to determine whether the controls were in HWE were eligible for a meta-analysis, but the influence of these studies on the pooled result was examined in subgroup analyses. Second, the quality of each study was assessed according to the NOS specific to case-control study \[[@R45]\]. The NOS evaluates the quality of a study in three domains: selection, comparability, and exposure. For each study, a maximum score of 4 is assigned for selection, 2 for comparability, and 3 for exposure. A study is considered low (or high) quality if total NOS score is \< 6 (or ≥ 6). Because the NOS score is a continuum, distinction between high and low quality is inevitably arbitrary. Due to the subjective nature, the NOS score was used as a stratification factor in the subgroup analysis to evaluate whether the results of the meta-analysis depended on the quality of the included studies \[[@R68]\].

Procedures of meta-analyses {#s4_4}
---------------------------

To clarify whether there was a joint effect between the rs1801516 polymorphism and radiation exposure in carcinogenesis, we performed three steps: 1). meta-analysis of the rs1801516 polymorphism and cancer risk in individuals in the presence of radiation exposure; 2). meta-analysis of the rs1801516 polymorphism and cancer risk in individuals in the absence of radiation exposure; 3). comparison of the differences in the effect estimates of the rs1801516 polymorphism on cancer risk between the two groups.

Subgroup meta-analyses were conducted based on pre-specified interests, including cancer site, ethnicity, familial cancer history, study quality, sample size, and HWE in controls. The criteria for a subgroup analysis required at least 3 studies. We aimed at determining whether the result of the overall meta-analysis was stable or dependent on some features of the included studies. Sensitivity analysis was conducted by excluding 1 study at a time and analyzing the remaining ones to explore whether the result was influenced by a particular study.

Statistical analysis {#s4_5}
--------------------

ORs and 95% CIs were used to assess the strength of the association between cancer risk and the rs1801516 polymorphism. The ORs were calculated under four genetic models: (1) heterozygous model (AG versus GG), (2) homozygous model (AA versus GG), (3) dominant model (AA+AG versus GG), and (4) recessive model (AA versus AG+GG). The statistical significance of the ORs was evaluated by using the Z test. In case of zero cells, an appropriate continuity correction (addition of 0.5 in all the cells) was implemented \[[@R69]\]. Between-study heterogeneity was evaluated by using the Cochrane Q test and the I^2^ statistic. We used the random effects model (DerSimonian and Laird\'s method \[[@R70]\]) to calculate the ORs when the *P value* of the Cochrane Q test was \< 0.10 or the I^2^ value was \> 50%; otherwise, the fixed effects model was applied. The test of interaction proposed by Altman et al. \[[@R71]\] was used to compare differences in effect estimates between subgroups. When there were more than 10 studies in a meta-analysis, we estimated publication bias by visualizing funnel plots and by Egger\'s linear regression test \[[@R72]\] and Begg\'s rank correlation test \[[@R73]\]. To assess deviation from HWE, we performed the appropriate goodness-of-fit χ2 test. The above statistical analyses were performed by using Stata, version 12, software (StataCorp LP, College Station, Texas) with 2-sided *P value*s. Statistical significance was defined as *P* \< 0.05.
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